article = {ACO-2020-3-101}
title = {Daclatasvir Plus Sofosbuvir With and Without Ribavirin for Previously Treated or Untreated Chronic HCV Infection Genotype 1, 2 and 4 in Togo}
journal = {Annals of Clinical Oncology}
year = {2020}
issn = {2674-3248}
doi = {http://dx.doi.org/10.31487/j.ACO.2020.03.01}
url = {https://www.sciencerepository.org/daclatasvir-plus-sofosbuvir-with-and-without-ribavirin-for-previously_ACO-2020-3-101 
author = {Folly  Anyovi,Reham Soliman,Lidaw Déassoua Bawe,Albert Theophane Yonli,Simplice Damitoti Karou,Jacques Simpore,Gamal  Shiha,}
keywords = { Génotype 1, 2, 4, hepatitis C, sofosbuvir/daclatasvir, patients naïfs, Togo}
abstract ={Background: Daclatasvir (DCV) is a potent, pangenotypic nonstructural protein 5A inhibitor with
demonstrated antiviral efficacy when combined with sofosbuvir (SOF) with or without ribavirin (RBV) in
patients with chronic hepatitis C virus (HCV) infection. We are using SOF-DCV combination for large scale
treatment.
Objectives: The aim of the current study was designed to investigate the efficacy and safety of
sofosbuvir/daclatasvir, with or without ribavirin for previously treated or untreated in treatment of HCV
genotype 1, 2 and 4, as well as their effect on the liver fibrosis.
Methods: One hundred twenty-seven patients with chronic HCV infection were categorized into 2 groups.
The group 1 comprised treatment naïve patients, with total serum bilirubin ≤ 1.2mg/10-1L, serum albumin
≥ 3,5g/10-1L, ALAT ≥ 3N, ASAT≤ 2N and platelets count 150 x 109
/L. The group 2 included Peg-INF-alpha
or sofosbuvir treatment-experienced patients or patients having at least 2 of the following characteristics:
total bilirubin ≤ 1.2mg/10-1L, serum albumin ≥ 3,5g/10-1L, ALAT ≥ 3N, ASAT ≤ 2N and platelets count 150
x 109
/L. The first group was treated with sofosbuvir/daclatasvir for 12 weeks except sofosbuvir treatment
experienced patients, who were treated with sofosbuvir/daclatasvir + ribavirin for 24 weeks, with generic
medications: DCV 60 mg plus SOF 400 mg ± ribavirin (RBV) within the treatment of hepatitis C virus
infection. Efficacy and safety were assessed, and baseline factors associated with sustained virological
response at post-treatment week 12 (SVR12) were explored.
Results: Sustained virological response (SVR12), was 95,8% in group 1 and 93,8% in group 2. Such high
efficacy was accompanied with tolerable adverse effects as well as with significant improvement in liver
fibrosis.
Conclusion: SOF plus DCV with or without ribavirin achieved high efficacy and safety in HCV genotypes
1,2 and 4 patients. Their effect was accompanied with attenuation of liver fibrosis. Further wider-scale
studies are needed to evaluate the actual role of IL 18 polymorphism in treatment response with
Sofosbuvir/Daclatasvir.}